论文部分内容阅读
目的探讨甲羟孕酮对改善晚期乳腺癌患者化疗期间生活质量的影响。方法将116例晚期乳腺癌患者随机分为对照组(56例)和观察组(60例),对照组患者接受紫杉醇联合表柔比星化疗方案,21d为1个周期,2个周期后评估疗效。观察组患者同时接受口服甲羟孕酮。比较两组患者近期疗效、化疗期间饮食、体重、KPS评分及药物不良反应。结果观察组患者治疗有效率与对照组比较,差异无统计学意义(73.3%和69.6%,P>0.05)。化疗期间观察组进食量、体重及KPS评分增加患者的比例显著多于对照组(P<0.05);观察组患者Ⅲ~Ⅳ级白细胞减少、脱发及恶心呕吐发生率显著少于对照组(P<0.05)。结论甲羟孕酮可显著减少晚期乳腺癌患者化疗期间的不良反应、改善饮食情况及生活质量。
Objective To investigate the effect of medroxyprogesterone on improving quality of life in patients with advanced breast cancer during chemotherapy. Methods One hundred and sixty-six patients with advanced breast cancer were randomly divided into control group (56 cases) and observation group (60 cases). Patients in control group received paclitaxel combined with epirubicin chemotherapy and 21 days for one cycle. The efficacy was evaluated after 2 cycles . Patients in the observation group also received oral medroxyprogesterone. The short-term curative effect, diet, body weight, KPS score and adverse drug reactions were compared between the two groups. Results The effective rate of treatment in observation group was not significantly different from that in control group (73.3% vs 69.6%, P> 0.05). The patients in observation group had significantly more food intake, body weight and KPS score during chemotherapy than those in control group (P <0.05). The incidences of grade Ⅲ ~ Ⅳ leukopenia, hair loss and nausea and vomiting in observation group were significantly less than those in control group (P < 0.05). Conclusion Medroxyprogesterone can significantly reduce adverse reactions during chemotherapy in advanced breast cancer patients and improve diet and quality of life.